The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

CHEMBL81398     1-hydroxypyridin-2-one

Synonyms: SureCN40240, SureCN112186, ACMC-1BOLD, AG-B-82628, AG-C-18541, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of AIDS081859

  • The present study analyzes the iron mobilization, the cytoprotective, and the antiproliferative effects of the lipophilic hydroxypyridinone CP411, in comparison with the hydrophilic chelator CP20 or deferiprone used in the treatment of iron overload [1].
  • The iron chelating hydroxypyridinone, CP94, has been administered prophylactically to iron overloaded gerbils in a dosing regime which favors the formation of bidentate chelated iron, to examine the possibility of additional toxicity being caused to the liver and heart by the bidentate chelated iron complex [2].

High impact information on AIDS081859


Biological context of AIDS081859


Anatomical context of AIDS081859


Associations of AIDS081859 with other chemical compounds


Gene context of AIDS081859

  • Deferiprone (L1; CP20) is an orally absorbed bidentate hydroxypyridinone iron chelator that can induce urinary iron excretion, promote negative iron balance and reduce hepatic iron levels in some transfusion-dependent patients, particularly in those who are markedly iron overloaded and have not received regular deferoxamine therapy [10].
  • Effect of orally active hydroxypyridinone iron chelators on human lymphocyte function [11].
  • These analogues contain one, two, or three bidentate 2,3-dihydroxyterephthalamide (TAM) units in place of the 3,2-hydroxypyridinone (HOPO) units on the parent hexadentate ligand [12].

Analytical, diagnostic and therapeutic context of AIDS081859


  1. Iron mobilization, cytoprotection, and inhibition of cell proliferation in normal and transformed rat hepatocyte cultures by the hydroxypyridinone CP411, compared to CP20: a biological and physicochemical study. Gaboriau, F., Chantrel-Groussard, K., Rakba, N., Loyer, P., Pasdeloup, N., Hider, R.C., Brissot, P., Lescoat, G. Biochem. Pharmacol. (2004) [Pubmed]
  2. Potentiation of iron accumulation in cardiac myocytes during the treatment of iron overload in gerbils with the hydroxypyridinone iron chelator CP94. Carthew, P., Smith, A.G., Hider, R.C., Dorman, B., Edwards, R.E., Francis, J.E. Biometals (1994) [Pubmed]
  3. Iron mobilization from hepatocyte monolayer cultures by chelators: the importance of membrane permeability and the iron-binding constant. Porter, J.B., Gyparaki, M., Burke, L.C., Huehns, E.R., Sarpong, P., Saez, V., Hider, R.C. Blood (1988) [Pubmed]
  4. The environment of the lipoxygenase iron binding site explored with novel hydroxypyridinone iron chelators. Abeysinghe, R.D., Roberts, P.J., Cooper, C.E., MacLean, K.H., Hider, R.C., Porter, J.B. J. Biol. Chem. (1996) [Pubmed]
  5. The relationship of intracellular iron chelation to the inhibition and regeneration of human ribonucleotide reductase. Cooper, C.E., Lynagh, G.R., Hoyes, K.P., Hider, R.C., Cammack, R., Porter, J.B. J. Biol. Chem. (1996) [Pubmed]
  6. Deferoxamine augments growth and pathogenicity of Rhizopus, while hydroxypyridinone chelators have no effect. Boelaert, J.R., Van Cutsem, J., de Locht, M., Schneider, Y.J., Crichton, R.R. Kidney Int. (1994) [Pubmed]
  7. Contrasting interspecies efficacy and toxicology of 1,2-diethyl-3-hydroxypyridin-4-one, CP94, relates to differing metabolism of the iron chelating site. Porter, J.B., Abeysinghe, R.D., Hoyes, K.P., Barra, C., Huehns, E.R., Brooks, P.N., Blackwell, M.P., Araneta, M., Brittenham, G., Singh, S. Br. J. Haematol. (1993) [Pubmed]
  8. The chelation of nonheme iron within sickle erythrocytes by the hydroxypyridinone chelator CP094. Hartley, A., Rice-Evans, C. Arch. Biochem. Biophys. (1992) [Pubmed]
  9. 2-Hydroxypyridine-N-oxides: effective new chelators in iron mobilisation. Kontoghiorghes, G.J. Biochim. Biophys. Acta (1987) [Pubmed]
  10. A risk-benefit assessment of iron-chelation therapy. Porter, J.B. Drug safety : an international journal of medical toxicology and drug experience. (1997) [Pubmed]
  11. Effect of orally active hydroxypyridinone iron chelators on human lymphocyte function. Pattanapanyasat, K., Webster, H.K., Tongtawe, P., Kongcharoen, P., Hider, R.C. Br. J. Haematol. (1992) [Pubmed]
  12. Terephthalamide-containing analogues of TREN-Me-3,2-HOPO. Jurchen, K.M., Raymond, K.N. Inorganic chemistry. (2006) [Pubmed]
  13. Enhancement of 5-aminolaevulinic acid-induced photodynamic therapy in normal rat colon using hydroxypyridinone iron-chelating agents. Curnow, A., McIlroy, B.W., Postle-Hacon, M.J., Porter, J.B., MacRobert, A.J., Bown, S.G. Br. J. Cancer (1998) [Pubmed]
WikiGenes - Universities